|
PL2391638T3
(pl)
*
|
2009-02-02 |
2018-11-30 |
Glaxosmithkline Biologicals Sa |
Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania
|
|
KR20120139672A
(ko)
|
2009-11-09 |
2012-12-27 |
젠벡, 인코포레이티드 |
원숭이 아데노바이러스 벡터의 증식 방법
|
|
US9526777B2
(en)
*
|
2010-04-16 |
2016-12-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein
|
|
AU2011332025B2
(en)
*
|
2010-11-23 |
2015-06-25 |
The Trustees Of The University Of Pennsylvania |
Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
|
|
WO2012089231A1
(en)
|
2010-12-30 |
2012-07-05 |
Okairòs Ag |
Paramyxovirus vaccines
|
|
TWI623618B
(zh)
|
2011-07-12 |
2018-05-11 |
傳斯堅公司 |
Ｈｂｖ聚合酶突變體
|
|
WO2013045668A2
(en)
|
2011-09-29 |
2013-04-04 |
Transgene Sa |
Immunotherapy composition and regimen for treating hepatitis c virus infection
|
|
TW201318637A
(zh)
|
2011-09-29 |
2013-05-16 |
Transgene Sa |
免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
|
|
JP6757120B2
(ja)
|
2011-10-05 |
2020-09-16 |
ジェンヴェック エルエルシー |
アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法
|
|
US9233153B2
(en)
*
|
2011-10-05 |
2016-01-12 |
Genvec, Inc. |
Affenadenovirus (gorilla) or adenoviral vectors and methods of use
|
|
CN103987726B
(zh)
|
2011-10-05 |
2017-10-03 |
金维克有限公司 |
猴(大猩猩)腺病毒或腺病毒载体及其使用方法
|
|
US20130122038A1
(en)
|
2011-11-14 |
2013-05-16 |
The United States Of America As Represented By The Secretary Of The Department |
Heterologous prime-boost immunization using measles virus-based vaccines
|
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
SI2825640T1
(sl)
|
2012-03-12 |
2016-08-31 |
Crucell Holland B.V. |
Šarže rekombinantnega adenovirusa s spremenjenimi konci
|
|
RU2737765C2
(ru)
|
2012-05-04 |
2020-12-02 |
Пфайзер Инк. |
Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
|
|
SG11201407343XA
(en)
*
|
2012-05-18 |
2014-12-30 |
Univ Pennsylvania |
Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
|
|
HK1210475A1
(en)
|
2012-05-29 |
2016-04-22 |
Genvec, Inc. |
Herpes simplex virus vaccine
|
|
EP3842068A1
(en)
|
2012-07-05 |
2021-06-30 |
GlaxoSmithKline Biologicals S.A. |
Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
|
|
WO2014005643A1
(en)
*
|
2012-07-05 |
2014-01-09 |
Okairos Ag |
Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
|
|
US10106781B2
(en)
|
2012-11-16 |
2018-10-23 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant adenoviruses and use thereof
|
|
SG11201507393TA
(en)
|
2013-03-14 |
2015-10-29 |
Salk Inst For Biological Studi |
Oncolytic adenovirus compositions
|
|
WO2014139587A1
(en)
|
2013-03-15 |
2014-09-18 |
Okairòs Ag |
Improved poxviral vaccines
|
|
KR102236497B1
(ko)
|
2013-04-25 |
2021-04-06 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
|
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
|
MX384992B
(es)
|
2014-06-13 |
2025-03-14 |
Glaxosmithkline Biologicals Sa |
Combinaciones inmunógenas.
|
|
PT3188753T
(pt)
|
2014-09-03 |
2020-03-25 |
Bavarian Nordic As |
Métodos e composições para induzir imunidade protetora contra infeção por filovírus
|
|
CA2960096A1
(en)
|
2014-09-03 |
2016-03-10 |
Bavarian Nordic A/S |
Methods and compositions for enhancing immune responses
|
|
WO2017025782A1
(en)
|
2014-09-17 |
2017-02-16 |
Glaxosmithkline Biologicals Sa |
Improved poxviral vaccines
|
|
KR102608590B1
(ko)
|
2014-09-24 |
2023-12-01 |
솔크 인스티튜트 포 바이올로지칼 스터디즈 |
종양 살상 바이러스 및 이의 사용방법
|
|
CN106999571B
(zh)
|
2014-09-26 |
2020-10-02 |
贝斯以色列护理医疗中心有限公司 |
诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物
|
|
EP4523756A3
(en)
|
2015-02-13 |
2025-05-28 |
Transgene |
Immunotherapeutic vaccine and antibody combination therapy
|
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
|
JP6735288B2
(ja)
|
2015-04-14 |
2020-08-05 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス
|
|
WO2016184822A1
(en)
|
2015-05-15 |
2016-11-24 |
Curevac Ag |
Prime-boost regimens involving administration of at least one mrna construct
|
|
GB201514772D0
(en)
*
|
2015-08-19 |
2015-09-30 |
Glaxosmithkline Biolog Sa |
Adenovirus polynucleotides and polypeptides
|
|
BR112017026523A2
(pt)
*
|
2015-06-12 |
2018-08-14 |
Glaxosmithkline Biologicals Sa |
vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado.
|
|
BE1024824B1
(fr)
*
|
2015-06-12 |
2018-07-13 |
Glaxosmithkline Biologicals Sa |
Polynucleotides et polypeptides d'adenovirus
|
|
US10457708B2
(en)
|
2015-07-07 |
2019-10-29 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F polypeptides
|
|
EA039065B1
(ru)
|
2015-07-07 |
2021-11-29 |
Янссен Вэксинс Энд Превеншн Б.В. |
Вакцина против rsv
|
|
GB201513176D0
(en)
*
|
2015-07-27 |
2015-09-09 |
Glaxosmithkline Biolog Sa |
Novel methods for inducing an immune response
|
|
DK3584252T3
(da)
|
2015-12-15 |
2021-11-15 |
Janssen Vaccines & Prevention Bv |
Human immundefektvirus-antigener, -vektorer, -sammensætninger og fremgangsmåder til anvendelse deraf
|
|
MX2018008797A
(es)
|
2016-01-19 |
2018-11-29 |
Pfizer |
Vacunas contra el cancer.
|
|
WO2017147269A1
(en)
|
2016-02-23 |
2017-08-31 |
Salk Institute For Biological Studies |
Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
|
|
WO2017147265A1
(en)
|
2016-02-23 |
2017-08-31 |
Salk Institute For Biological Studies |
High throughput assay for measuring adenovirus replication kinetics
|
|
JP7466271B2
(ja)
|
2016-03-31 |
2024-04-12 |
ザ ヨーロピアン モレキュラー バイオロジー ラボラトリー |
アデノウイルスコートタンパク質由来送達賦形剤
|
|
JP7233928B2
(ja)
|
2016-04-05 |
2023-03-07 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Ｒｓｖに対するワクチン
|
|
IL262108B2
(en)
|
2016-04-05 |
2023-04-01 |
Janssen Vaccines Prevention B V |
Soluble pre-fusion rsv f proteins are stabilized
|
|
CA3023022A1
(en)
|
2016-05-04 |
2017-11-09 |
Transgene Sa |
Combination therapy with cpg tlr9 ligand
|
|
CN109154000B
(zh)
|
2016-05-12 |
2022-07-05 |
扬森疫苗与预防公司 |
有效和平衡的双向启动子
|
|
CN109311946A
(zh)
|
2016-05-30 |
2019-02-05 |
扬森疫苗与预防公司 |
稳定化的融合前rsv f蛋白
|
|
RU2745500C2
(ru)
|
2016-06-20 |
2021-03-25 |
Янссен Вэксинс Энд Превеншн Б.В. |
Эффективный и сбалансированный двунаправленный промотор
|
|
GB2549809C
(en)
|
2016-06-23 |
2022-11-30 |
Univ Oxford Innovation Ltd |
Vector
|
|
EP3484507A1
(en)
|
2016-07-15 |
2019-05-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against a marburg virus infection
|
|
WO2018011198A1
(en)
|
2016-07-15 |
2018-01-18 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against a marburg virus infection
|
|
EP3504230A1
(en)
|
2016-08-23 |
2019-07-03 |
GlaxoSmithKline Biologicals SA |
Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
|
|
WO2018060288A1
(en)
|
2016-09-29 |
2018-04-05 |
Glaxosmithkline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
WO2018069316A2
(en)
|
2016-10-10 |
2018-04-19 |
Transgene Sa |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
|
ES2959811T3
(es)
*
|
2016-12-09 |
2024-02-28 |
Glaxosmithkline Biologicals Sa |
Construcciones de adenovirus de chimpancé con antígenos de Lyssavirus
|
|
EP3532082A4
(en)
|
2016-12-12 |
2020-08-26 |
Salk Institute for Biological Studies |
SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
|
|
GB201701239D0
(en)
*
|
2017-01-25 |
2017-03-08 |
Glaxosmithkline Biologicals Sa |
Novel formulation
|
|
US11034978B2
(en)
|
2017-02-09 |
2021-06-15 |
Janssen Vaccines & Prevention B.V. |
Potent and short promoter for expression of heterologous genes
|
|
EP3606553A1
(en)
|
2017-04-06 |
2020-02-12 |
Janssen Vaccines & Prevention B.V. |
Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
|
|
EP3634449A4
(en)
|
2017-05-08 |
2021-03-17 |
Gritstone Oncology, Inc. |
ALPHAVIRUS NEOANTIGEN VECTORS
|
|
WO2018209113A1
(en)
*
|
2017-05-10 |
2018-11-15 |
University Of Utah Research Foundation |
Compositions and methods of use of arc capsids
|
|
WO2018210871A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
|
AU2018267971A1
(en)
|
2017-05-17 |
2019-11-07 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against RSV infection
|
|
KR20200015759A
(ko)
|
2017-06-15 |
2020-02-12 |
얀센 백신스 앤드 프리벤션 비.브이. |
Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법
|
|
ES2906441T3
(es)
*
|
2017-07-05 |
2022-04-18 |
Nouscom Ag |
Secuencias de ácidos nucleicos y de aminoácidos del adenovirus de los grandes simios no humanos, vectores que las contienen y usos de las mismas
|
|
KR20200027551A
(ko)
|
2017-07-11 |
2020-03-12 |
화이자 인코포레이티드 |
Cea muc1 및 tert를 포함하는 면역원성 조성물
|
|
JP7298926B2
(ja)
|
2017-07-12 |
2023-06-27 |
ノイスコム アーゲー |
癌の治療のためのネオアンチゲンワクチン組成物
|
|
WO2019016756A1
(en)
|
2017-07-21 |
2019-01-24 |
Glaxosmithkline Biologicals Sa |
ANTIGEN CONSTRUCTS OF CHIKUNGUNYA VIRUSES
|
|
CN111163799A
(zh)
|
2017-07-28 |
2020-05-15 |
扬森疫苗与预防公司 |
用于异源repRNA免疫接种的方法和组合物
|
|
SG11202001458SA
(en)
|
2017-09-15 |
2020-03-30 |
Janssen Vaccines & Prevention Bv |
Method for the safe induction of immunity against rsv
|
|
EP3697919A1
(en)
|
2017-10-16 |
2020-08-26 |
GlaxoSmithKline Biologicals SA |
Adenoviral vectors with two expression cassettes encoding rsv antigenic proteins or fragments thereof
|
|
EP3697902A1
(en)
|
2017-10-16 |
2020-08-26 |
GlaxoSmithKline Biologicals S.A. |
Enhanced promoter
|
|
JP2021500880A
(ja)
|
2017-10-16 |
2021-01-14 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
２つの発現カセットを有するサルアデノウイルスベクター
|
|
WO2019076877A1
(en)
|
2017-10-16 |
2019-04-25 |
Glaxosmithkline Biologicals Sa |
ADENOVIRAL VECTORS FOR REPLICATION
|
|
WO2019086450A1
(en)
*
|
2017-10-31 |
2019-05-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
|
WO2019086461A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus vectors and uses thereof
|
|
WO2019086466A1
(en)
*
|
2017-10-31 |
2019-05-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
|
CN111372943B
(zh)
*
|
2017-10-31 |
2023-12-05 |
扬森疫苗与预防公司 |
腺病毒及其用途
|
|
KR102747530B1
(ko)
|
2017-11-03 |
2024-12-27 |
노우스콤 아게 |
백신 t 세포 인핸서
|
|
WO2019099970A1
(en)
|
2017-11-20 |
2019-05-23 |
Janssen Pharmaceuticals Inc. |
Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
|
|
US11773142B2
(en)
|
2017-12-11 |
2023-10-03 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant adenoviruses and uses thereof
|
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
|
KR20200100745A
(ko)
|
2017-12-19 |
2020-08-26 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물
|
|
BR112020012361A2
(pt)
|
2017-12-20 |
2020-11-24 |
Glaxosmithkline Biologicals S.A. |
constructos de antígeno do vírus epstein-barr
|
|
CN112292449A
(zh)
|
2018-04-09 |
2021-01-29 |
萨克生物研究学院 |
具有增强的复制特性的溶瘤腺病毒组合物
|
|
EP3807298A1
(en)
|
2018-06-12 |
2021-04-21 |
GlaxoSmithKline Biologicals S.A. |
Adenovirus polynucleotides and polypeptides
|
|
EP3581201A1
(en)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 proteins and uses thereof
|
|
EP3587581A1
(en)
|
2018-06-26 |
2020-01-01 |
GlaxoSmithKline Biologicals S.A. |
Formulations for simian adenoviral vectors having enhanced storage stability
|
|
EP3810277A1
(en)
|
2018-07-20 |
2021-04-28 |
Janssen Vaccines & Prevention B.V. |
Recombinant adenoviral vector expressing zika antigen with improved productivity
|
|
GB201812647D0
(en)
*
|
2018-08-03 |
2018-09-19 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Viral vectors and methods for the prevention or treatment of cancer
|
|
US12576143B2
(en)
*
|
2018-10-19 |
2026-03-17 |
Nouscom Ag |
Teleost invariant chain cancer vaccine
|
|
MX2021005607A
(es)
|
2018-11-13 |
2021-06-30 |
Janssen Vaccines & Prevention Bv |
Proteinas f de prefusion del vrs estabilizadas.
|
|
MX2021005656A
(es)
|
2018-11-15 |
2021-07-07 |
Nouscom Ag |
Seleccion de mutaciones de cancer para la generacion de una vacuna contra cancer personalizada.
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
CA3132601A1
(en)
|
2019-03-05 |
2020-09-10 |
Glaxosmithkline Biologicals Sa |
Hepatitis b immunisation regimen and compositions
|
|
CN113573741B
(zh)
*
|
2019-03-20 |
2024-07-26 |
国立大学法人北海道大学 |
修饰腺病毒和含有其的医药
|
|
MX2021014525A
(es)
*
|
2019-05-30 |
2022-03-17 |
Gritstone Bio Inc |
Adenovirus modificados.
|
|
US20220372515A1
(en)
*
|
2019-10-03 |
2022-11-24 |
Janssen Vaccines & Prevention B.V. |
Adenovirus vectors and uses thereof
|
|
WO2021092095A1
(en)
*
|
2019-11-04 |
2021-05-14 |
Gritstone Oncology, Inc. |
Neoantigen vaccine therapy
|
|
CR20220220A
(es)
|
2019-11-18 |
2022-09-20 |
Janssen Biotech Inc |
Vacunas basadas en calr y jak2 mutantes y sus usos
|
|
CN113088530A
(zh)
*
|
2020-01-08 |
2021-07-09 |
怡道生物科技(苏州)有限公司 |
一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法
|
|
JP2023512519A
(ja)
|
2020-01-31 |
2023-03-27 |
ベス イスラエル ディーコネス メディカル センター インコーポレイテッド |
コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
WO2021209897A1
(en)
|
2020-04-13 |
2021-10-21 |
Janssen Biotech, Inc. |
Psma and steap1 vaccines and their uses
|
|
CA3183086A1
(en)
|
2020-05-11 |
2021-11-18 |
Janssen Pharmaceuticals, Inc. |
Stabilized coronavirus spike protein fusion proteins
|
|
US20230233661A1
(en)
|
2020-06-29 |
2023-07-27 |
Janssen Vaccines & Prevention B.V. |
Vaccine combination against repiratory syncytial virus infection
|
|
US20230035403A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Method For Determining Responsiveness To Prostate Cancer Treatment
|
|
US20230024133A1
(en)
|
2020-07-06 |
2023-01-26 |
Janssen Biotech, Inc. |
Prostate Neoantigens And Their Uses
|
|
CN113897388B
(zh)
*
|
2020-07-06 |
2024-05-31 |
嘉兴安宇生物科技有限公司 |
一种新型黑猩猩腺病毒载体及其构建方法和应用
|
|
EP4175664A2
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
US20230302119A1
(en)
|
2020-07-06 |
2023-09-28 |
Janssen Pharmaceuticals, Inc. |
Stabilized Corona Virus Spike Protein Fusion Proteins
|
|
IL299571A
(en)
|
2020-07-08 |
2023-02-01 |
Janssen Sciences Ireland Unlimited Co |
Rna replicon vaccines against hbv
|
|
CN116322740A
(zh)
|
2020-07-13 |
2023-06-23 |
特兰斯吉恩股份有限公司 |
免疫抑制的治疗
|
|
CN116438308A
(zh)
*
|
2020-08-06 |
2023-07-14 |
磨石生物公司 |
多表位疫苗盒
|
|
US12275766B2
(en)
|
2020-12-23 |
2025-04-15 |
Janssen Biotech, Inc. |
Neoantigen peptide mimics
|
|
WO2022175477A1
(en)
|
2021-02-19 |
2022-08-25 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion rsv fb antigens
|
|
WO2022175479A1
(en)
|
2021-02-19 |
2022-08-25 |
Janssen Vaccines & Prevention B.V. |
Vaccine combinations against respiratory syncytial virus strain a and b infections
|
|
KR20230165275A
(ko)
|
2021-04-01 |
2023-12-05 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정화된 융합 전 piv3 f 단백질
|
|
WO2022218997A1
(en)
|
2021-04-12 |
2022-10-20 |
Centre National De La Recherche Scientifique (Cnrs) |
Novel universal vaccine presenting system
|
|
KR20240024800A
(ko)
|
2021-06-21 |
2024-02-26 |
노우스콤 아게 |
암호화된 아주반트를 포함하는 백신 조성물
|
|
WO2023020939A1
(en)
|
2021-08-17 |
2023-02-23 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023026182A1
(en)
|
2021-08-24 |
2023-03-02 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023047348A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized corona virus spike protein fusion proteins
|
|
WO2023047349A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized coronavirus spike protein fusion proteins
|
|
WO2023111725A1
(en)
|
2021-12-14 |
2023-06-22 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
EP4448802A1
(en)
|
2021-12-16 |
2024-10-23 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion hmpv fusion proteins
|
|
WO2023198815A1
(en)
|
2022-04-14 |
2023-10-19 |
Janssen Vaccines & Prevention B.V. |
Sequential administration of adenoviruses
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
WO2024061759A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Stabilized coronavirus s proteins
|
|
WO2024061757A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Pre-fusion human piv1 f proteins
|
|
WO2024074584A1
(en)
|
2022-10-06 |
2024-04-11 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion piv3 f proteins
|
|
WO2025158316A1
(en)
|
2024-01-26 |
2025-07-31 |
Janssen Biotech, Inc. |
Ovarian neoantigens and use thereof
|